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Abstract: Treatment of animal African trypanosomiasis (AAT) requires urgent need for safe, potent
and affordable drugs and this has necessitated this study. We investigated the trypanocidal activities
and mode of action of selected 3-aminosteroids against Trypanosoma brucei brucei. The in vitro
activity of selected compounds of this series against T. congolense (Savannah-type, IL3000),
T. b. brucei (bloodstream trypomastigote, Lister strain 427 wild-type (427WT)) and various multi-drug
resistant cell lines was assessed using a resazurin-based cell viability assay. Studies on mode of
antitrypanosomal activity of some selected 3-aminosteroids against Tbb 427WT were also carried
out. The tested compounds mostly showed moderate-to-low in vitro activities and low selectivity
to mammalian cells. Interestingly, a certain aminosteroid, holarrhetine (10, IC50 = 0.045 ± 0.03 µM),
was 2 times more potent against T. congolense than the standard veterinary drug, diminazene aceturate,
and 10 times more potent than the control trypanocide, pentamidine, and displayed an excellent
in vitro selectivity index of 2130 over L6 myoblasts. All multi-drug resistant strains of T. b. brucei
tested were not significantly cross-resistant with the purified compounds. The growth pattern of
Tbb 427WT on long and limited exposure time revealed gradual but irrecoverable growth arrest at
≥ IC50 concentrations of 3-aminosteroids. Trypanocidal action was not associated with membrane
permeabilization of trypanosome cells but instead with mitochondrial membrane depolarization,
reduced adenosine triphosphate (ATP) levels and G2/M cell cycle arrest which appear to be the result
of mitochondrial accumulation of the aminosteroids. These findings provided insights for further
development of this new and promising class of trypanocide against African trypanosomes.
Keywords: African trypanosomiasis; Trypanosoma brucei brucei; Trypanosoma congolense; mode of
action; resistant strains
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1. Introduction
Animal African trypanosomiasis (AAT), a severe wasting disease of domestic livestock, is caused
predominantly by T. congolense, T. vivax and T. b. brucei [1]. To date, it has remained a major threat
to livestock production in sub-Saharan Africa [2,3]. With a high mortality rate of 20–50% within
months of infecting cattle compounded by the lack of vaccine, and the steady increase in reported
cases of drug resistance, AAT has remained a threat to food security in the affected regions [4,5].
It is endemic in 37 sub-Saharan countries where about 50 million cattle are at risk of contracting the
disease, while deterring the importation of horses, high-yield dairy cattle and other non-indigenous
domestic animals that are particularly vulnerable to AAT, to the further detriment of agricultural
production [6]. To combat AAT, an estimated 35 million doses of trypanocides per year are used [7] in
the prevention and treatment of the disease, still leaving over two thirds of the cattle population in
these areas vulnerable to infection [3]. The economic consequences of AAT are evident from losses
estimated at $4.5 billion per year [8], and considering the increasing failure of the few available drugs,
now reported in 21 African countries [9,10], this is projected to rise further. In the past, the focus
has been predominantly on the control and elimination of human African trypanosomiasis (HAT,
or sleeping sickness). However, with HAT targeted for elimination by the World Health Organization
(WHO) and patient numbers rapidly decreasing due to sustained efforts by international and national
agencies [11,12], there is a need to refocus attention on identifying novel, potent, safe and affordable
remedies for the corresponding livestock condition, given that the main control strategy for AAT is
chemotherapy. The worrying epidemiological trends of AAT, in addition to the reported resistance
of trypanosomes to diminazene (the most widely used trypanocide for AAT [13]), necessitates an
alternative and efficient remedy, and natural products have often shown promise in this regard.
Steroid alkaloids, present in the Apocynaceae, Buxaceae, Solanaceae and Liliaceae families, are an
emerging class of trypanocides, with the 3-aminosteroids as the leading class of steroid alkaloids,
displaying particularly strong antitrypanosomal activities [14,15] relative to other chemical classes.
Clearly, there is a need to explore this for further development. Following our previous findings
on lead identification and subsequent refinement of the quantitative structure-antitrypanosomal
(QSAR)/cytotoxic activities relationship of steroid alkaloids from Holarrhena africana (Apocynaceae)
against T. brucei species and L6 mammalian myoblast [16], there is a need to further study their
activities against AAT-causing trypanosomes, including their mode of trypanocidal activity and
whether cross-resistance with diminazene is likely to occur.
Determining the mode of action of a drug is imperative to understand the interaction of the
biomolecule in the context of its use, since this will influence literally all further steps of the
drug discovery and development process [17]. The antimicrobial actions of natural compounds
are usually complex and the reported cellular or biochemical effects are often not the primary
causes of phenotypic observations, due to the compounds interacting with off-target proteins and
multiple targets [18–20], especially in trypanosomatids, which are characterized by complex and
unusual biochemical processes [21]. However, such mechanistic studies are necessary to give further
insights into their antitrypanosomal action, which, supplemented with the theoretical findings on
3D-QSAR [16], may be used to optimize such compounds from hits to leads and further on to new
and specific drugs. Thus, the compound’s potency, its target within the parasites’ physiology and the
potential to withstand the development of resistance, especially cross-resistance with the existing set
of drugs, have all to be considered to identify and develop new antiparasite chemotherapy.
Here, against the backdrop of our continued effort towards the development of 3-aminosteroid lead
compounds, we report the trypanocidal activities of some 3-aminosteroids against Trypanosoma congolense
(Tc-IL3000, Savannah type strain), wild-type strain of Trypanosoma brucei brucei (Tbb 427WT) and some
resistant strains derived from the wild type and further present observations on the mode of action of
two selected 3-aminosteroids against T. brucei species.
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2. Results
2.1. Pentacyclic 3-Aminosteroids Are More Active against Tc-IL3000 Than Tbb 427WT
The in vitro activities (IC50, µM) of the 3-aminosteroids 1–10 against Tbb 427WT and Tc-IL3000
and their chemical structures are shown in Table 1. All the compounds tested showed moderate
activities (IC50, 1.6–4.8 µM) against T. b. brucei. In contrast, their effects against Tc-IL3000 covered
a much wider range, including much more potent in vitro activities, in the mid-nanomolar range
(IC50, 0.045–20.8 µM); most compounds (6/10) were more potent against T. congolense, in a few cases
dramatically so. 10 was approximately twice as potent against Tc-IL3000 as the most widely used AAT
trypanocide, diminazene aceturate, and was 10 times better against this species than the control HAT
trypanocide, pentamidine. Generally, pentacyclic 3-aminosteroids (6–10) were more active (IC50 <
1.6 µM) against Tc-IL3000 than the tetracyclics (1–5) with IC50 > 2.9 µM, and displayed a much greater
differentiation between the two trypanosome species.
Table 1. In vitro activities of some 3-aminosteroids against wild-type T. b. brucei (Tbb 427WT)
and Tc-IL3000.
Compounds
Tbb 427WT Tc-IL3000
IC50, µM S. I. IC50, µM S. I.
1
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4.79 ± 0.81 20.4 0.045 ± 0.03 2130 
 Pentamidine 0.004 ± 0.001 - 0.448 ± 0.28 - 
 Diminazene  0.066 ± 0.002 - 0.093 ± 0.01 - 
Data are average of three independent determinations and expressed as mean IC50 ± standard 
deviation (SD); selectivity indices (S.I.) = cytotoxic (IC50) on L6 cell/IC50 target cell; the IC50 values for 
cytotoxicity against L6 rat skeletal myoblasts as well as against T. b. rhodesiense have been reported 
elsewhere [14]. 
1.62 ± 0.09 10.5 6.08 4.97 2.8
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Table 1. Cont.
Compounds
Tbb 427WT Tc-IL3000
IC50, µM S. I. IC50, µM S. I.
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2.2. Cross Resistance of 3-Aminosteroids with Standard Trypanocid s
The aminoster ids were retes ed on a panel of ell-documente T. b. bruc i strains that display
resistance or increased sensitivity to sp cific clinic l and experimental trypanocides: from TbAT1-KO,
the TbAT1/P2 transporter has been deleted, rendering it strongly resistant to diminazene and slightly
resistant to pentamidine and arsenicals [22]; B48 was derived from TbAT1 by exposure to pentamidine
and gained strong resistance to pentamidine and arsenicals [23]; ISMR1 is resistant to isometamidium
and cross-resistant to diminazene [24]; R0.8 is resistant to cAMP phosphodiesterase inhibitors [25];
from AQP2/3-knockout (KO) the locus with AQP2 and AQP3 was deleted, rendering it resistant to
pentamidine [26]; and AQP1-3 KO was derived from the AQP2/3 knockout by additionally deleting the
TbAQP1 gene, causing hypersensitivity to inhibitors of trypanosome alternative oxidase (TAO) [27,28].
The in vitro activities against drug resistant cell lines of T. brucei were largely comparable to
the wild-type strain; even when differences occurred, sensitivity was mostly within 2-fold relative
to control wild-type cultures. Interestingly, however, compounds 3 and 5, displayed a significant
level of resistance with either one or both of the two cell lines lacking the P2/TbAT1 aminopurine
transporter, which reached statistically significance (p < 0.05) (Table 2). It is interesting to note that
these are the only two 3-amino congeners in this set with the amino function in position 3α, indicating
that such aminosteroids might be substrates for this famously versatile aminopurine/diamidine
transporter [29–31] and that the recognition is stereo-specific. However, this moderate loss of activity
is less than the generally high levels of resistance to the control drugs diminazene and pentamidine
in the strains lacking P2/TbAT1, indicating that the uptake of aminosteroids 3 and 5 is not as
completely dependent on P2/TbAT1 than it is for the aromatic diamidines. Importantly, no cross
resistance was observed with the 3β-aminosteroids—an essential requirement for new trypanosomiasis
drugs—except 7, which displayed a low but significant loss of sensitivity to all strains except the
AQP-KO trypanosomes. Based on the results of the in vitro activity and the cross resistance profile of
all the compounds studied, 3β-holaphyllamine (1) and 3β-N-methylholaphyllamine (2) were chosen
for further studies on their mode of action.
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Table 2. In vitro activities and cross resistance profile of selected 3-aminosteroids against some Tbb 427WT-derived resistant cell lines.
Compound
TbAT1-KO AQP1-3-KO AQP2/3-KO ISMR B48 R0.8
IC50 (µM) RF IC50 (µM) RF IC50 (µM) RF IC50 (µM) RF IC50 (µM) RF IC50 (µM) RF
1 3.2 ± 0.6 0.7 3.6 ± 0.2 0.8 6.6 ± 0.5 1.4 7.2 ± 0.8 1.6 4.4 ± 0.2 0.9 2.6 ± 0.3 0.6
2 1.6 ± 0.2 0.9 1.5 ± 0.2 0.9 2.7 ± 0.2 1.5 2.9 ± 0.9 1.7 2.3 ± 0.4 1.3 1.1 ± 0.1 0.6
3 19 ± 0.3 *** 5.6 4.7 ± 0.2 1.4 9.1 ± 1.0 ** 2.7 11.0 ± 0.5 *** 3.2 17.4 ± 0.8 *** 5.1 5.3 ± 0.6 1.6
4 5.5 ± 0.4 1.4 2.7 ± 0.3 0.7 5.8 ± 0.4 1.4 8.0 ± 0.5 * 2.0 7.8 ± 0.7 1.9 5.9 ± 0.6 1.5
5 1.7 ± 0.1 1.0 1.4 ± 0.1 0.9 2.6 ± 0.4 1.6 2.9 ± 0.3 1.8 3.5 ± 0.05 *** 2.1 1.7 ± 0.6 1.1
6 >100 - >100 - >100 - >100 - >100 - >100 -
7 8.2 ± 0.2 *** 2.4 1.7 ± 0.2 0.5 3.4 ± 0.2 1.0 10 ± 0.4 *** 2.9 8.2 ± 0.1 *** 2.4 6.0 ± 0.9* 1.8
8 4.2 ± 0.1 1.2 4.6 ± 0.2 1.3 4.1 ± 0.1 1.2 2.7 ± 0.1 0.8 3.5 ± 0.4 1.0 3.4 ± 0.2 1.0
9 2.1 ± 0.1 0.9 1.8 ± 0.2 0.8 3.2 ± 0.3 1.4 3.7 ± 1.0 1.7 3.4 ± 0.2 1.6 2.6 ± 0.2 1.2
10 3.3 ± 0.2 0.7 1.4 ± 0.2 0.3 3.3 ± 0.1 0.7 6.2 ± 0.8 1.3 4.6 ± 0.1 0.9 2.6 ± 0.1 0.5
PMD a 0.0077 ± 0.0002 ** 2.0 0.058 ± 0.003 *** 15 0.046 ± 0.002 *** 12 0.0065 ± 0.0010 * 1.7 0.55 ± 0.07 ** 143 0.0072 ± 0.0004 ** 1.9
DA b 0.47 ± 0.02 *** 7.0 ND - ND - 1.1 ± 0.1 *** 17 0.74 ± 0.04 *** 11 ND -
a PMD, pentamidine; b DA, diminazene aceturate; RF = resistance factor = IC50 (resistant strain)/IC50 (Tbb 427WT). RF ≈ 1 or < 1 indicates no prospect for cross resistance; RF >> 1
indicates the possibility of cross resistance; RF > 1 indicates reduced potency RF < 1 indicates increased potency. p-values were calculated using the unpaired Student’s t-test (n = 3);
* p < 0.05; ** p < 0.01; *** p <0.001 are significantly different from wild-type control values in Table 1. ND, not determined.
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2.3. Effects on Growth Patterns of T. b. brucei Cells after Short and Long Duration of Exposure
The growth patterns of T. b. brucei cells incubated with 1 and 2 in Hirumi’s modified Iscove’s
medium (HMI-9) growth media were compared with untreated cells. Both 1 and 2 caused a slow-onset
growth arrest of the cells at concentrations at or above their respective IC50 values (Figure 1) with no
chances of recovery from the early effects of the compounds, even after only a brief exposure of 2 h
(panels C and D). However, cells incubated with either compound at half their IC50 concentrations
recovered from the effects and resumed growth comparable to cells in the absence of treatment.
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Figure 1. Growth curves of wild-type T. b. brucei grown in the continuous presence of 1 (A) or 2 (B) 
and in Hirumi’s modified Iscove’s medium (HMI-9) standard growth media after a short incubation 
period (2 h) with 1 (C) or 2 (D). 
2.4. Propidium Iodide (PI) Assay of Cellular Integrity. 
The time of onset of anti-trypanosomal action of compounds 1 or 2 on T. b. brucei was determined 
by propidium iodide (PI) assay based on the principle that damaged cells become fluorescent as PI 
dye begins to enter them and binds to nucleic acids. As PI is not taken up by intact trypanosomes, 
this can only occur when the plasma membrane is compromised as a result of loss of cellular integrity 
caused directly or indirectly by 1 or 2. The effects of varying concentrations (1×, 2× and 4× the IC50 
values) of 1 and 2 on the cell viability were monitored over a 6 h period (Figure 2). Both compounds 
showed slow but concentration-dependent trypanosomal membrane disruption effects. The time of 
onset of action was observed to be within 3–4 h of incubation, with peak effects achieved within 4 h. 
Figure 1. Growth curves of wild-type T. b. brucei grown in the continuous presence of 1 (A) or 2 (B)
and in Hirumi’s modified Iscove’s medium (HMI-9) standard growth media after a short incubation
period (2 h) with 1 (C) or 2 (D).
2.4. Propidium Iodide (PI) Assay of Cellular Integrity
The time of onset of anti-trypanosomal action of compounds 1 or 2 on T. b. brucei was determined
by propidium iodide (PI) assay based on the principle that damaged cells become fluorescent as PI dye
begins to enter them and binds to nucleic acids. As PI is not taken up by intact trypanosomes, this can
only occur when the plasma membrane is compromised as a result of loss of cellular integrity caused
directly or indirectly by 1 or 2. The effects of varying concentrations (1×, 2× and 4× the IC50 values)
of 1 and 2 on the cell viability were monitored over a 6 h period (Figure 2). Both compounds showed
slow but concentration-dependent trypanosomal membrane disruption effects. The time of onset of
action was observed to be within 3–4 h of incubation, with peak effects achieved within 4 h.
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Figure 2. Speed of action profile of 3-aminosteroids. The profiles represent fluorescence intensity of 
nucleic acid–propidium iodide (PI) complex for T. b. brucei incubated with 1 (red traces) and 2 (black 
traces) at concentrations 1×, 2× and 4× IC50 values and controls: Digi, digitonin (blue trace; positive 
control for 100% cellular disruption); Untr, PI + untreated cells only (Tan trace); and no cell, PI 
background without cells (green trace, ‘no cells’). 
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Treatment with several 3-aminosteroids resulted in alterations in cellular morphology as 
described above. Fluorescence-activated cell sorting (FACS) flow cytometric analysis was carried out 
to determine the DNA content and, hence, establish the effects of 3-aminosteroids on T. b. brucei cell 
cycle stages (G1, S, G2/M or cytokinesis) (Figure 3, and supplementary Figure S1 for gating strategy 
and other details). The results showed a gradual and very similar decrease in the population of the 
G1 cell population and an increase in the G2/M phase for 1 and 2, both at concentrations of 4× EC50. 
There was also an observable effect on S cell cycle stage by either compound as the population of 
DNA in the phase, although appearing relatively constant, was clearly diminished relative to the 
control treated with the same volume of DMSO only (Figure 3). These observations seem to indicate 
fewer cells entering the S-phase, but S-phase cells still mostly progressing to G2/M phase, leading to 
the conclusion that DNA synthesis was not principally affected; 2 appeared to have a slightly more 
noticeable effect than 1 on the trypanosome cell cycle stages with the accumulation of about 40% 
DNA at the G2/M cell cycle phase after 10 h of incubation (Figure 3A) compared with about 35% 
observed in 1 (Figure 3B). The group treated with solvent only (DMSO) displayed the same 
configurations as an untreated control group assessed in parallel (not shown). 
Microscopic examination of cell populations exposed for 12 h to 2× the respective EC50 
concentrations of 1 or 2 prior to DAPI staining revealed swollen, misshapen cells, apparently 
containing replicated nuclear and kinetoplast DNA apparently stuck at G2/M phase as few cells 
contained more than one nucleus or kinetoplast (Figure 4), further confirming the above observed 
effects on DNA content analysis. 
The number of nuclei (N) and kinetoplasts (K) per cell was monitored in the population by 
counting 500 cells and scoring them for the number of each DNA-containing organelle. Cells 
containing 2 nuclei and 2 kinetoplasts were further divided into early and late categories (2N2K-e, 
2N2K-l) depending whether a clear ingression furrow for the longitudinal cell division could be 
observed. After 8 h of incubation with 1× EC50 of 1 or 2 cells started to appear that could not be 
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virtually identical for 1 and 2 throughout. Over the 24 h of the experiment, the number of 1N1K cells 
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Figure 2. Speed of action profile of 3-aminosteroids. The profiles represent fluorescence intensity
of nucleic acid–propidium iodide (PI) complex for T. b. brucei incubated with 1 (red traces) and 2
(black traces) at concentrations 1×, 2× and 4× IC50 values and controls: Digi, digitonin (blue trace;
positive control for 100% cellular disruption); Untr, PI + untreated cells only (Tan trace); and no cell,
PI background without cells (green trace, ‘no cells’).
2.5. Influence of 3-Aminosteroids on DNA Content/Cell Cycle of Wild-Type T. b. brucei
Treatment with several 3-aminosteroids resulted in alterations in cellular morphology as described
above. Fluor scence-activated cell sorting (FACS) flow cytometric analysis was carried out to determine
the DNA content and, hence, establish th effects of 3-aminosteroids on T. b. brucei cell cycle stages
(G1, S, G2/M or cytokinesis) (Figure 3, and upplementary Figure S1 for gating trategy and other
detail ). The results showed a gradual and v ry similar decrease in the population of the G1 cell
population and an incr ase in the G2/M phase for 1 an 2, both at conc ntr tions of 4× EC50. There was
also an observable effect on S ell cycle stage by either compound as the population of DNA in the phase,
although appeari g relative y cons ant, was clearly diminished relative to the control treated with
the same volume of DMSO only (Figure 3). These observ tions seem to in icate fewer cells en ering
the S-phase, but S-phase cells sti l ostly progressing to G2/M phase, leading o the conclus on that
DNA synth sis was not principally affected; 2 appeared t have a slightly m re noticeabl effect than
1 on the trypanosome cell cycle tages with the accumulation of about 40% DNA at the G2/M cell
cycle phase after 10 h of incubation (Figure 3A) compared with about 35% observed in 1 (Fig re 3B).
The group treated with solv nt only (DMSO) displayed the same configurati ns as an untreated control
group assessed in parallel (not shown).
Microscopic examination f cell p pul tions exposed for 12 h to 2× the respective EC50
concentrations of 1 or 2 prior to DAPI staining revealed swoll n, misshapen cells, apparently ontaining
replicated nuclear and kinetoplas DN apparently stuck at G2/M phase a few cells cont ined more
than o e nucleus or ki etoplast (Figur 4), further confirming the above observed effects on DNA
ent analysis.
The number of uclei (N) and kinetoplasts (K) per cell was monitored in the population by
counting 500 cells and scoring them for th number of each DNA-containing organelle. Cells contai ing
2 nuclei and 2 kinetopla ts were further divided into early and late categories (2N2K- , 2N2K-l)
dependi whether a clear ingression fur ow for the longitudinal cell division could be observed.
After 8 h of incubation wit 1× EC50 of 1 or 2 cells started to appear that could not be classified in th
regular categories and these were scored as ‘other’ (Figure 5). Observati ns w re virtually identical
for 1 an 2 througho t. Over the 24 h of experiment, the numb r of 1N1K cells progressively and
significantly in reased relative t the control culture. Concurr ntly, th re was a prog essive decline
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in the number of 2N2K (early and late) cells, and the emergence of cells with an irregular DNA
configuration as the cell structure deteriorated.
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Figure 3. DNA content of T. b. brucei cells for (A) = cells treated with 4× EC50 1; (B) = cells treated with 
4× EC50 2; error bars represent SD; data for frequency in population. Graphs depict DNA content 
collected by flow cytometry. The percentages of each cell cycle stage were plotted as a frequency of 
the total cell population (%) over 12 h. 
 
Figure 4. Morphological examination of DAPI-stained treated (with DMSO, 1 or 2) and untreated T. 
b. brucei 427WT cells; the marked cells (black and white arrow heads) were representative cells with 
characteristic effects on size, morphology, motility and configuration post-treatment with 1 or 2. 
Figure 3. DNA content of T. b. brucei cells for (A) = cells treated with 4× EC50 1; (B) = cells treated
with 4× EC50 2; error bars represent SD; data for frequency in population. Graphs depict DNA content
collected by flow cytometry. The percentages of each cell cycle stage were plotted as a frequency of the
total cell population (%) over 12 h.
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Figure 5. Cell configuration in DAPI stained cell populations. Samples were taken at the indicated 
times from cultures incubated with or without test compounds 1 and 2, stained with the nucleic acid 
dye DAPI and observed by fluorescence microscopy. For each sample, 500 cells were scored in 
categories for the number of kinetoplasts (K) and nuclei (N), with the sub-classification early (e) 
indicating the absence of an ingression furrow for cell division, and late (l) indication a clear presence 
of an ingression furrow. Each bar represents the average and SD of two independent experiments. In 
each category, the treated samples were statistically compared to the treated sample by unpaired t-
test. * p < 0.05; ** p < 0.01. For the category ‘others’ no statistical comparison could be performed as no 
‘others’ were observed in the control culture. Observation and scoring of cells were done using a Zeiss 
Axioskop fluorescence microscope. 
Figure 5. Cell configuration in DAPI stained cell populations. Samples were taken at the indicated
times from cultures incubated with or without test compounds 1 and 2, stained with the nucleic
acid dye DAPI and observed by fluorescence microscopy. For each sample, 500 cells were scored
in categories for the number of kinetoplasts (K) and nuclei (N), with the sub-classification early (e)
indicating the absence of an ingression furrow for cell division, and late (l) indication a clear presence
of an ingression furrow. Each bar represents the average and SD of two independent experiments.
In each category, the treated samples were statistically compared to the treated sample by unpaired
t-test. * p < 0.05; ** p < 0.01. For the category ‘others’ no statistical comparison could be performed as
no ‘others’ were observed in the control culture. Observation and scoring of cells were done using a
Zeiss Axioskop fluorescence microscope.
Molecules 2019, 24, 268 10 of 20
The morphology of the cells was studied in more detail by higher-resolution fluorescence
microscopy with a DeltaVision Core microscope (Applied Precision, GE Healthcare Life Siences,
Amersham, Bucks, UK). Figure 6 shows Delta Core images of cells stained with DAPI and MitoTracker
after incubation for 8 h with 1× EC50 of 1 and 2, and control unexposed cells. Some of the cells
incubated for 8 h with either compound appeared to have larger, elongated nuclei compared to
control cells (average nuclear volume increased to 152% (p = 0.0012) and 120% (p = 0.12) of control
at 8 h of culture), but otherwise the cells had not noticeably changed as a result of this mild
exposure, and staining with mitotracker did not reveal any mitochondrial damage at this point.
The mitochondrion also appeared to be intact, an indication that 3-aminosteroids may not directly
affect mitochondrial integrity. The untreated cells retained the typical trypomastigote shape throughout
the duration of the experiment. After 8 h, some more highly damaged and even lysed cells began to
appear (not shown).
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2.6. Influence of 3-Aminosteroids on Mitochondrial Membrane Potential (MMP) 
We next investigated the influence of 1 and 2 on MMP. The MMP of untreated cells remained 
fairly unchanged while the positive controls troglitazone and valinomycin caused a strong and rapid 
hyperpolarization and depolarization of MMP, respectively. The 3-aminosteroids were found to 
cause a slower but significant depolarization of the MMP (Figure 7A). Both compounds induced a 
gradual MMP depolarization effect, observed as early as 2 h of incubation, which was statistically 
Figure 6. High-resolution fluorescence microscopy of individual cells observed with wide-field
deconvolution fluorescence microscope. In the overlay, cyan is DAPI, yellow is MitoTracker.
Representative images, taken of random cells (blind study). Scale bars are 5 µm.
2.6. Influence of 3-Aminosteroids on Mitochondrial Membrane Potential (MMP)
We next investigated the influence of 1 and 2 on MMP. The MMP of untreated cells remained
fairly unchanged while the positive controls troglitazone and valinomycin caused a strong and rapid
hyperpolarization and depolarization of MMP, respectively. The 3-aminosteroids were found to
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cause a slower but significant depolarization of the MMP (Figure 7A). Both compounds induced a
gradual MMP depolarization effect, observed as early as 2 h of incubation, which was statistically
significant for 2 (p < 0.05). From 4 h the decrease was significant for both treatments, and it continued
to drop to approximately 20% at 12 h. At the chosen concentration of 2× EC50, 2 had a stronger MMP
depolarizing effect than 1, although this difference only showed minor significance at the 2 h point
(p < 0.05), and may thus reflect a more rapid internalization of 2.
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Figure 7. Effects of 3-aminosteroids 1 and 2 on mitochondrial membrane potential (A) and intracellular
ATP level (B) of Tbb 427WT, each at 2× EC50 concentration. * p < 0.05; ** p < 0.01; *** p < 0.001 indicate
significant difference from the corresponding untreated control at the same time point (unpaired
Student’s t-test (n = 3)); error bars = ± SD.
2.7. Influence of 3-Aminosteroids on Intracellular ATP Levels
Further studies to assess any cause-effect relationship between T. b. brucei intracellular ATP level
and the earlier observed effects were undertaken. The results showed that 3-aminosteroids rapidly and
significantly (p < 0.05) decreased the ATP level in T. b. brucei (Figure 7B). The pattern closely followed
that observed for the decrease in MMP, with 2 inducing a slightly more rapid and deeper decline than
1 for the concentrations chosen, but both otherwise following very much the same trend.
3. Discussion
The 3-aminosteroids showed impressive activities against the more virulent of the two haematic
parasites, Tc-IL3000, than against T. b. brucei. Both parasites, in addition to T. vivax, cause Nagana in cattle
but they can also cause serious losses in pigs, camels, goats, dogs and sheep. With 2 (IC50 = 1.75 µM)
and 5 (IC50 = 1.62 µM) being the most active compounds against T. b. brucei under our experimental
conditions, it can be inferred that 3-aminosteroids are moderately active against T. b. brucei while
much higher levels of activity had previously been determined against the human pathogen, T. b.
rhodesiense, using a different protocol [14]. It is important to note that, using an assay such as the
resazurin-based one, EC50 values are not constants, but very much dependent on the duration of
incubation and the cell density, and should be taken as a ranking that is internally consistent but not
absolute. The protocol that is used as standard in the De Koning lab is particularly rigorous and tends
to give substantially higher EC50 values for some classes of compounds than similar assays that use
much lower cell densities.
Our observation regarding the structure-antitrypanosomal (SAR) of the 3-aminosteroids is that
methylation of the 3-amino substituent and the stereochemistry at the C-3 position affects the activity
against T. b. brucei, and particularly against T. congolense. For instance, the monomethylated 3-amino
derivatives were more active than the non-methylated and dimethylated derivatives, as evidenced
by comparing 2, 7 and 9 with 1, 8 and 10 respectively. The α-congeners were similarly more potent
than the corresponding β-congeners, comparing 3 and 5 with 1 and 4 respectively, which might in
part be attributable to their apparent uptake through the TbAT1/P2 transporter, as judged by the
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significantly reduced sensitivity to strains lacking this carrier. There was a very clear contribution of
the additional pyrroline ring, formed from the C-18-N-C-20 bridge, to the activities of 3-aminosteroids
against Tc-IL3000, as observed by comparing 1–5 vs. 6–10. Interestingly, 10 (IC50 (Tc) = 0.045 µM),
was ~2 times more active than the widely used veterinary drug diminazene aceturate [1] and 10 times
more active than another well-known trypanocide, pentamidine, which is the standard treatment for
early-stage HAT [32]. Hence, there will be a need to further explore its activity against T. congolense
and carry out further SAR. The relatively higher activities and SI against Tc-IL3000 (up to 2130)
of the pentacyclic compounds 6–10 strongly indicate a different mechanism for this aminosteroid
series (whereas the very similar EC50 values for series 1–5 point for a similar mode of action against
T. congolense and T. brucei), likely to be rooted in the biochemical and molecular differences between
these species [33]. As a T. congolense-specific drug would not act against human sleeping sickness,
and would have limited utility for AAT, where the infecting species is almost never known, we have
here prioritised the general trypanocides 1 and 2.
The emergence of resistant parasites in both the laboratory and the field suggest that these
parasites are readily capable of adapting under drug pressure [34] although it has been found
impossible to induce resistance to some natural compounds, including curcumin [35]. Resistance
to the current trypanocidal drugs is a major bottleneck to the control of these severe vector-borne
diseases [36,37] and trypanosomes resistant to almost all the available drugs have been identified [9,38].
In order to avoid introducing new trypanocides that have resistance profiles similar to that of the
standard treatments, lead compounds should be subjected to cross-resistance studies. In this study,
we found almost no significant differences in the susceptibility of various drug-resistant strains and
the wild-type T. b. brucei to most of the compounds, and almost all observed resistance factors were
below 2.5-fold. Significant increases in IC50 values were observed following treatment with compound
3 against TbAT1-KO (5.6), AQP2/3-KO (2.7), ISMR (3.2) and B48 (5.1), 5 against B48 (2.1) and 7 against
TbAT1 (2.4), ISMR (2.9) and B48 (2.4), which indicated a somewhat reduced potency against these
resistant strains. However, these figures are insignificant when compared with the resistance factors
of these resistant strains against the standard drugs. Furthermore, there were no similar comparable
tendencies for the other aminosteroids tested, emphasising that there is no cross-resistance problem
for this pharmacological class as a whole, and that the 3β-aminosteroids, in particular, are unlikely
to exhibit any cross resistance with existing first line HAT and AAT drugs such as pentamidine,
melarsoprol, cymelarsan, isometamidium or diminazene, whose resistance mechanisms have been
well characterised [22,24,37]. The data from the cross-resistance study indicate that 3-aminosteriods,
being structurally dissimilar to any current trypanocides, are most unlikely to be internalized through
the same drug transporters (possible exception for TbAT1/P2 and 3α-aminosteroids), or rely on
the same intracellular target, and the presented data are consistent with this notion. Aside from the
conclusion about resistance-associated transporters such as TbAT1/P2 [22,37], TbAQP2/HAPT1 [37,39]
and the low-affinity pentamidine transporter LAPT [23,40], the absence of resistance with R0.8 indicates
that the 3-aminosteroids do not act on the trypanosome’s cAMP signalling system [25], and the similar
IC50 values against ISMR show that the test compounds have probably no direct effect on the FoF1
ATPase [24].
In the presence of continuous or time-limited (2 h) exposure to the 3-aminosteroids at concentrations
≥IC50, the growth pattern of Tbb 427WT was disrupted with no possibility of recovery, although
complete clearance was not observed until 2–3 days after exposure. The early growth arrest in both
cases and the complete clearance observed after 72 h of incubation suggest that 3-aminosteroids are
trypanocidal and, like diamidines, prone to act very slowly but irreversibly [41]. The early effects on
trypanosomes being irreversible once initiated is an undoubted advantage for in vivo efficacy as a short
exposure time reduces potential cytotoxicity associated with the maintenance of peak drug plasma
levels over an extended period of time. Of crucial importance for the treatment of AAT, moreover,
is that it is in most cases impractical to have to administer multiple doses, over an extended time,
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to the infected animal. To introduce such a drug would be to practically ensure non-compliance,
which would lead to relapses and promote rapid-onset resistance.
PI is a red fluorophore that is not taken up by live, intact trypanosomes but does enter, and bind
to trypanosome nucleic acids, when the plasma membrane is compromised as a result of loss of
cellular integrity [42,43]. The effects of 3-aminosteroids differ significantly from digitonin, a known
cell membrane lysis agent, which causes rapid trypanosome cell permeabilization reaching maximum
fluorescence in the first few minutes [44]. The much slower, concentration-dependent membrane
permeabilization effect of the 3-aminosteroids suggests that these compounds do not directly cause
membrane leakage by a physicochemical effect as their main mode of action, but rather that over time
an increasing number of cells becomes sufficiently permeable to PI to elicit a fluorescence response.
It should be noted that, while loss of cellular integrity obviously allows binding of PI to trypanosomal
nucleic acids, not all cellular entry of PI is necessarily indicative of cell death having already occurred
(as opposed to a small increase in membrane permeability), and that it does not reveal whether cell
death occurs by necrosis or apoptosis, as some features of necrosis and apoptosis may be shared [45].
The slow trypanocidal effects of 3-aminosteroids as observed from the growth patterns and
PI-based assay leaves the likely target of the compounds open. Thus, it was explored whether these
compounds target aspects of the cell cycle, bearing in mind the unusual cell cycles of kinetoplastids,
in which the nucleus, kinetoplast and basal body replicate and segregate in a coordinated fashion
into daughter cells during cell division [46–48]. The PI-associated fluorescence after binding to
T. brucei DNA is proportional to the amount of DNA per cell when analysed by flow cytometry [43,49].
This revealed a possible stall during the G2/M cell cycle phase, as the cells with double the DNA
content of non-dividing cells progressively increased after treatment with either 1 or 2 (Figure 4 and
Figure S1), although there was no increase, but rather a gradual decrease in the number of nuclei
(Figures 6 and 7). These findings suggest that DNA replication was unaffected, but that instead mitosis
was inhibited, leading to significantly enlarged nuclei, with increased DNA content. In bloodstream
form (BSF) T. brucei, inhibition of mitosis (M) prevents cytokinesis, although not re-replication of
nuclear DNA (at G2 phase) and kinetoplast DNA (at S phase), or segregation of replicated kinetoplasts
(at G2 phase), resulting in cells with a single enlarged nucleus and multiple kinetoplasts [50]. However,
no cells with multiple kinetoplasts but only 1 nucleus were observed, other than the regular 1N2K cells
that necessarily precede mitosis into 2N2K cells, and the proportion of those cells progressively and
dose-dependently declined. Thus, it appears that it is the failure to divide the mitochondrially-located
kinetoplasts that halts the cell cycle at that point and leads to the observed growth arrest and ultimate
cell death.
This is not entirely unexpected as the 3-aminosteroids are likely to accumulate in the trypanosomal
mitochondrion, by virtue of their lipophilicity and the cationic nature of their salts, formed in aqueous
media, which provides mitochondrial targeting similar to previous lipophilic cations that have shown
promise against African trypanosomes [27,51,52]. Mitochondrial destruction as their mode of action
could not be validated in the present studies as mitochondrial integrity remained intact, judging by
fluorescence microscopy following MitoTracker staining. However, the mitochondrial accumulation
has been associated with many different trypanocidal activities of various compounds disrupting
various mitochondrial functions. Examples are inhibitors of TAO coupled to lipo-cations [27];
di-cationic diamidines such as pentamidine and DB75 targeting multiple mitochondrial functions
including kinetoplast DNA through accumulation to high concentrations [53–55]; choline-based
di-cations disrupting mitochondrial functions [43]; bisphosphonium compounds inhibiting the activity
of the T. brucei F1-ATPase [43]; disruption of kDNA replication by ethidium [56]; selective cleavage
of kinetoplast DNA minicircles by diminazene and isometamidium [57]. Many of these drugs
have been documented to bind to, or otherwise affect, the kinetoplast, but in general terms the
principal consequence of the mitochondrial targeting of trypanocides is that they accumulate against a
concentration gradient to a very high intra-mitochondrial concentration, driven by the mitochondrial
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membrane potential (pentamidine accumulates to mM concentrations [58]). This makes it likely that
the drug can interfere with (multiple) biochemical processes in that space.
Although no direct mitochondrial damage was established after 8 h of incubation with 1× EC50
of 1 or 2, this does not rule out either mitochondrial accumulation or a mitochondrial target for
3-aminosteroids. It has been found that kDNA replication requires mitochondrial proteins [59] that are
encoded in the nuclear genome and imported into the mitochondrion. This import requires ATP and is
proton-motive force-driven and hence depends on the mitochondrial membrane potential (MMP) [60].
The BSFs of T. b. brucei have a less elaborate mitochondrial metabolism than almost any other aerobic
eukaryotic cell type; they lack the Krebs cycle enzymes as lack a cytochrome-dependent electron
transport chain [52]. Therefore, they rely entirely on glycolysis instead of oxidative phosphorylation
to generate ATP [61] and use the FoF1 ATPase to maintain mitochondrial membrane potential by
pumping protons over the inner mitochondrial membrane (IMM) from the matrix to the intermembrane
space [62]. We have previously reported that lipophilic bisphosphonium cations accumulate in the
mitochondrion, cause a depolarisation of the IMM and reduce the cellular ATP content by inhibiting
the F1 ATPase [52]. Although the lack of cross-resistance with the T. brucei ISMR strain, which derives
its isometamidium resistance from a mutation in the γ-subunit of F1 [24], suggests that this ATPase
is not the principal target of the aminosteroids, we found that, like the bisphosphonium salts and
isometamidium, 1 and 2 rapidly depolarise the IMM, with significant decline in MMP in 4 h and
2 h, respectively. We likewise observed a rapid decline in cellular ATP levels, which could cause the
IMM depolarisation, as this is directly maintained by ATP. Conversely, a functional mitochondrion is
essential for ATP production in BSF trypanosomes, although the glycolysis and ATP production actually
takes place in a unique trypanosomatid-specific organelle called the glycosome [63]. However, in order
to maintain redox balance, the glycolysis intermediate glycerol-3-phosphate must be oxidized back to
dihydroxyacetone phosphate by glycerol-3-phosphate dehydrogenase (G-3-PDH) in the mitochondrion,
transferring 4 electrons to ubiquinol, which is subsequently oxidized to ubiquinone by TAO which
then converts molecular oxygen to water [64,65]. This so-called glycerol-3-phosphate shuttle, and thus
mitochondrial respiration, is dependent on the MMP [66], and without it BSF trypanosomes generate
just one ATP per glucose, explaining the rapid and extreme decline in cellular ATP levels also observed
with the Fo inhibitor oligomycin [67]. Thus, MMP and ATP content are linked, as also observed for the
bisphosphonium compounds [52], but whereas those compounds caused an increase in G1-phase cells,
the 3-aminosteroids caused an increase of cells arrested in G2/M phase.
Overall, we conclude that 3-aminosteroids act on the trypanosomal mitochondrion, by which
they cause a strong reduction of the MMP, and ATP levels, and prevent the division of kinetoplast,
resulting in irreversible G2/M phase cell cycle arrest and eventual cell death. Further studies should
assess ultrastructural changes in the kinetoplast and the integrity of kDNA.
4. Materials and Methods
4.1. Parasites, Cell Lines and Cultures
The parasites used for this study include Trypanosoma congolense Tc-IL3000 (Savannah-type strain
IL 3000) [27], T. brucei brucei (BSF trypomastigotes T. b. brucei strain 427 Lister WT (Tbb 427WT),
MiTat 1.2/BS221) and six resistant cell lines of T. brucei brucei BSF trypomastigotes which have been
described [22–25,28,68]. All the T. b. brucei strains were cultured in standard Hirumi’s modified
Iscove’s medium 9 (HMI-9), supplemented with 10% heat-inactivated foetal bovine serum (FBS),
14 µL/L β-mercaptoethanol, and 3.0 g sodium hydrogen carbonate per litre of medium adjusted
to pH 7.4, Tc-IL3000 strains were cultured in Dulbecco’s minimum essential medium (MEM) with
β-mercaptoethanol, sodium pyruvate, sodium bicarbonate and supplemented with fresh goat serum.
All the parasites were cultured in vented flasks at 37 ◦C in a 5% CO2 atmosphere and were passaged
every 72 h.
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4.2. Determination of In Vitro Anti-Trypanosomal Activity of Compounds
All tested compounds were isolated from Holarrhena africana A. DC. (a synonym of H. floribunda
(G. Don) T. Durand & Schinz) (Apocynaceae) and identified as described in our previous
communication [14]; 1H- and 13C-nuclear magnetic resonance (NMR) spectra to assess the identity and
purity can be found in the supplementary information of [14]. The in vitro activities of 1–10 against
BSF trypanosomes were determined using a resazurin-based assay protocol as described [24,27,42]
using cell densities adjusted to 2 × 105 cells/mL for T. b. brucei and 5 × 105 cells/mL for Tc-IL3000.
Cells were exposed to at least 11 doubling dilutions of test compound starting at 100 µL, with the last
well in the row receiving medium without test compound as a drug-free control. The trypanosome
culture and test compounds were incubated for a period of 48 h at 37 ◦C for T. b. brucei and 32 ◦C
for Tc-IL3000 under a 5% CO2 atmosphere. In all the assays, pentamidine and diminazene aceturate
were used as positive controls. Fluorescence was measured in the 96-well plates with a FLUOstar
Optima (BMG Labtech, Aylesbury, Bucks, UK) at wavelengths of 544 nm for excitation and 590 nm
for emission. IC50 values were calculated by non-linear regression using an equation for a sigmoidal
dose-response curve with variable slope (Prism 5.0, GraphPad Software, San Diego, CA, USA).
4.3. Effect of Treatments on Growth Patterns of T. b. brucei after Short- and Long-Term Exposure
Varying concentrations of 1 and 2 were tested on trypanosomes in order to determine in vitro cell
growth patterns and time-to-kill. Trypanosomes at their mid logarithmic phase of growth were taken
from cultures and cell density was determined using a haemocytometer (Camlab, Over, UK). The cell
density was adjusted to 2 × 105 cells with fresh HMI-9 medium and the fresh cultures were incubated
with varying concentrations of 1 and 2 at 37 ◦C under a 5% CO2 atmosphere. For the limited time of
exposure assay, the cells were similarly incubated, but after 2 h of exposure to the test compounds,
the cells were washed twice with fresh HMI-9 media, re-seeded at the same cell density and again
incubated under the same conditions. At predetermined intervals, cell counts were taken from each
culture, typically for up to 72 h, and the counts were used for plotting the growth curves.
4.4. Determination of Speed of Action by Propidium Iodide (PI) Assay
100 µL of 18 µM PI in HMI-9 was added to each well of a 96-well plate. In the first column of the
wells, 200 µL solutions of test compound, also in 18 µM PI/HMI-9, was added and serially diluted
across the wells. Wells receiving only media without test compound served as drug-free controls.
To each well was added 100 µL of 2 × 106 T. brucei 427WT cells/mL in HMI-9. Wells containing the
same final concentration of 9 µM PI in HMI-9 but no cells served to record background fluorescence.
The plates were incubated in a FLUOstar OPTIMA fluorimeter at 37 ◦C with 5% CO2 atmosphere,
and the fluorescence was recorded at 544 nm excitation and 620 nm emission for 120 cycles at 180 s
per cycle.
4.5. Determination of Intracellular ATP Level
Intracellular ATP was measured using a Molecular Probes ATP Determination Kit (Molecular
Probes Inc., Cambridge, UK) following the manufacturer’s protocol. Trypanosome culture density was
adjusted to 107 cells/mL and incubated with 1 or 2. At predetermined time intervals, 1 mL parasites
culture was taken and centrifuged for 10 min at 2500× g, 4 ◦C. The resulting pellets were lysed by
sonication and cell debris was removed using a refrigerated microcentrifuge (SciQuip, Newtown,
UK) at 12,000× g for 10 min at 4 ◦C. The resultant supernatant was frozen in liquid nitrogen and
stored at −80 ◦C. For the analysis, 90 µL reaction solution from the master mix was added to each
designated well of a 96-well plate and the background luminescence was recorded using a FLUOstar
OPTIMA fluorimeter; then 10 µL of each sample was added to the well and incubated for 15 min at
28 ◦C and the luminescence was recorded. A standard curve was made using serial dilution of varying
concentrations of ATP (0.5–500 pM) to calculate the ATP concentrations in the samples.
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4.6. Effects of Treatments on Cell Morphology
A T. b. brucei culture was adjusted to 2 × 105 cell/mL and incubated with 1 and 2 for the duration
of the assay. The MitoTracker red CMXRos (New England Biolabs Ltd, Hitchin, UK) used for this
assay was prepared from a stock solution of 100 µM in DMSO. From this solution, 1 µL was added
to 1 mL of cell sample taken from the cell culture at each time point to make a final concentration of
100 nM of MitoTracker. The sample was then incubated at 37 ◦C and 5% CO2 for 5 min. The incubated
sample was washed in filter-sterilized 1× phosphate buffered saline (PBS) and spun at 2600× g for
10 min (4 ◦C). After the final wash step, the sample was re-suspended in 1 mL of 1× PBS. A 50 µL of
the re-suspended cells were spread onto a glass microscope slide (CamLab), previously coated with
50 µL of poly-L-lysine (Sigma-Aldrich, Gillingham, Dorset, UK); and were left to air dry, the cells
were then fixed in 4% paraformaldehyde/1× PBS for 10 min at room temperature. The slides were
covered with 1 mL of PBS and allowed to rehydrate for 10 min after which it was then allowed to
evaporate but not completely. A drop of Vectashield anti-fade mounting medium with DAPI (Vector
Laboratories, Burlingame, CA, USA) was added to the slides and spread by a coverslip (CamLab,
Over, UK); the coverslip was then applied and the edges were sealed with nail varnish. Slides were
observed for cell morphology under an Axioskop microscope (Image Solutions. Preston, UK) using
softWoRx software (Suite 2.0, Applied Precision, GE Healthcare, Amersham, Bucks, UK), while DNA
configuration was assessed using a Zeiss Axioplan microscope (Cambridge, UK) using Hamamatso
digital camera and Openlab software. For detailed observation of single DAPI-stained cells and the
measurement of nuclear volumes, Z-stacks of cells labelled for DAPI and MitoTracker were acquired
using an Olympus UPLSAPO 100× oil (1.40 NA) objective on a DeltaVision Core microscope (Applied
Precision, GE Healthcare Life Siences, Amersham, Bucks, UK) attached to a CoolSNAP HQ2 CCD
camera (Photometrics, Tucson, AZ, USA). Deconvolution was performed using SoftWoRx Suite 2.0),
and later data was analysed using FIJI [69] and/or IMARIS (Bitplane, Belfast, UK).
4.7. Determination of Mitochondrial Membrane Potential
FACS was employed in the determination of the changes in MMP due to exposure of T. b.
brucei to 1 and 2 by TMRE dye incorporation as previously described [43,52]. The cell density was
adjusted to 106 cells/mL and incubated with 1 or 2 at 32 ◦C under 5% CO2. At predetermined
intervals, 1 mL of sample was washed and re-suspended in 1 mL PBS containing 200 nM of TMRE in
FACS tubes, followed by incubation at 37 ◦C for 30 min, and analysed by a Becton Dickinson FACS
Calibur (Franklin Lakes, NJ, USA) using a FL2-heigth detector and CellQuest (Becton Dickinson) and
FlowJo software (V.10, Ashland, OR, USA). Valinomycin (100 nM; Sigma-Aldrich) and troglitazone
(10 µM; Sigma-Aldrich) were employed as mitochondrial membrane depolarizer and hyperpolarizer
control, respectively.
4.8. Determination of Cell Cycle and DNA Content Assay
FACS analysis was performed to study the effects of 1 and 2 on cell cycle of trypanosomes,
essentially as described previously [49] with the following modifications. Approximately 2.5 × 106
cells were harvested by centrifugation at 1500× g for 10 min at 4 ◦C and washed once in 1× PBS by
centrifugation (3000× g for 5 min). The cells were re-suspended in 1 mL of 70% ethanol and 30%
1× PBS. The tubes with the cells were left at −20 ◦C to fix overnight in the dark and the samples were
subsequently washed once with 1 mL 1× PBS, re-suspended in 500 µL 1× PBS containing 10 µg/mL
PI and 100 µg/mL RNase A and incubated at 37 ◦C for 45 min before FACS analysis. The samples were
analyzed by a Becton Dickinson FACSCalibur and PI incorporation was measured using the FL2-Area
detector and CellQuest software. The data obtained were analyzed using FlowJo software (V.10).
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Supplementary Materials: The following are available online. Figure S1: Details of the DNA content and cell
cycle analysis.
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